ClinicalTrials.Veeva

Menu
I

In Vivo | Bydgoszcz, Poland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Orforglipron
PF-04971729
LY3502970
Ertugliflozin
Vepugratinib
LY3866288
MK-8835
Pirtobrutinib
MK-8835-059

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 9 total trials

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocy...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Pirtobrutinib

The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiova...

Begins enrollment this month
Chronic Kidney Disease
Atherosclerosis Cardiovascular Disease
Drug: Orforglipron
Drug: Placebo

The GZPS master protocol will support two independent studies, J2A-MC-GZS1 and J2A-MC-GZS2. Each study will see how well and safely orforglipron work...

Enrolling
Urinary Incontinence,Stress
Drug: Placebo
Drug: Orforglipron

The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladde...

Not yet enrolling
Urinary Bladder Neoplasms
Neoplasm Metastasis
Drug: Vepugratinib
Drug: EV

Trial sponsors

Merck Sharp & Dohme (MSD) logo
Lilly logo
Loxo Oncology logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems